Article Sidebar

Submitted
14 August 2017
Accepted
14 August 2017
Published
15 August 2017
Download
PDF
Statistic
Read Counter : 2168 Download : 1074

Main Article Content

Abstract

Cisplatin is one of platinum cytostatic drug for the medication of solid cancers, one of which is head and neck cancer. Adverse event that resulted during drug treatment was acute or chronic nephrotoxicity. Cisplatin concentration in proximal tubular epithelial cells is about 5 times the serum concentration. Platinum exposure on renal tubular cells bonding covalent complex which stimulate production of inflammatory factors that lead to apoptosis and necrosis cell. Cisplatin nephrotoxicity can be prevented by aggressive hydration or alternate method of administration. The aim of this study was to analyze the effectiveness of NaCl-Mannitol hydration on renal function of head and neck cancer patients receiving cisplatin 100 mg/m2 chemotherapy combination with 5FU or paclitaxel. This was a cohort, prospective, and observational study to analyze renal function of head and neck cancer patients receiving cisplatin 100 mg/m2 chemotherapy combination with 5FU or paclitaxel. Inclusion criteria were BUN 7-18 mg/dl and serum creatinine < 2 mg/dl of any cycle. All patients received infuse NaCl-Mannitol hydration with term that provided in Surgeon Departement of Dr. Soetomo General Hospital. Data obtained were BUN, SCr, and eClCr Cockroft-Gault, each was measured pre- and post-hydration. In cisplatin and 5FU chemotherapy combination value BUN pre-hydration (11,99 + 4,62) mg/dl, value BUN post-hydration (12,14 + 4,74) mg/dl and value serum creatinine pre-hydration (0,97 + 0,34) mg/dl, value serum creatinine post-hydration (1,02 + 0,37) mg/dl. Meanwhile to the combination of cisplatin and paclitaxel chemotherapy, value BUN pre-hydration (10,19 + 2,58) mg/dl, value of BUN post-hydration (10,43 + 2,31) mg/dl and value of serum creatinine post- hydration (0,98 + 0,26) mg/dl. In conclusion, NaCl-Mannitol hydration administration is adequate which is shown by BUN and serum creatinine in pre- and post-hydration data within normal limits.

Keywords

hydration cisplatin nephrotoxicity serum creatinine BUN

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Desiani, E., Suharjono, S., Yulistiani, Y., & Susilo, D. H. (2017). ANALYSIS OF NACL-MANNITOL HYDRATION ON RENAL FUNCTION OF HEAD AND NECK CANCER PATIENTS RECEIVING HIGH-DOSE CISPLATIN CHEMOTHERAPY COMBINATION. Folia Medica Indonesiana, 53(1), 64–74. https://doi.org/10.20473/fmi.v53i1.5492
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Al-Sarraf M., Fletcher W., Oishi N., Pugh R., Hewlett J.S., Balducci L., McCracken J., Padilla F., 1982. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treatment Reports. Vol. 66 p.31–35
  2. Anderson, P.O., Knoben, J.E., Troutman, W.G., 2002. Handbook of Clinical Drug Data Tenth Edition. New York: McGraw-Hill. p.726-727
  3. Arany, I., Safirstein, R.L., 2003. Cisplatin nephron-toxicity. Seminars in Nephrology. Vol. 23 p.460–464
  4. Arunkumar, P.A., Mukund, H., Radheshyam, N., Belliyappa, M.S., 2011. Research Article – Clinical Evaluation of Cisplatin Induced Nephrotoxicity Characterized by Electrolyte Disturbances. Asian Pacific Journal of Tropical Biomedicine. p. 100-104.
  5. Arunkumar P.A., Viswanatha., Radheshyam N., Mukund H., Belliyappa., 2012., Science behind cisplatin induced nephrotoxicity in humans: a Clinical study., Asian Pacific Journal of Tropical Biomedicine p. 640-644
  6. Bagnis, C.I., Vacher, V.L., Karie, S., Deray, G., 2008. Anticancer Drugs., In: De Broe, M.E., Porter, G.A., Bennett, W.M., Deray G (eds): Clinical Nephrotoxins Renal Injury from Drugs and Chemicals Third Edition. New York: Springer. p. 513-515
  7. BC Cancer Agency Drug Manual, 2008. Cisplatin. p. 1-11.
  8. Colevas, A.D., 2006. Review Article : Chemotherapy Option for Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. Vol. 24. Number 17. p. 2644-2652
  9. Cornelison, T.L., Reed, E., 1993. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecologic Oncology Vol. 50 p. 147–158.
  10. Dahlan, M. S., 2013. Besar Sampel dan Cara Peng-ambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Salemba Medika, Jakarta. Edisi 3, Cetakan Kedua. hal. 21
  11. DeVita, V.T., Hellman, S., Rosenberg, S.A., 2005. Cancer: Principles & Practice of Oncology 7th Edition. Lippincott William & Wilkins. p. 658-671
  12. Dewi, I.S., Santoso, H., Yulistiani, Yahya, M., 2013. Evaluasi Fungsi Ginjal Pasien Kanker Serviks yang Mendapat Cisplatin Dosis 75 mg/m2 dengan Hidrasi NaCl-Manitol (Studi di IRNA SMF/Departemen Ilmu Obstetri dan Ginekologi). Fakultas Farmasi, Universitas Airlangga, Surabaya
  13. Frick, G.A., Ballentine, R., Driever, C.W, Kramer, W.G., 1979. Renal excretion kinetics of high dose cis-dichlorodiammineplatinum(II) administered with hydration and manitol diuresis. Cancer Treatment Reports Vol. 63 p.13-16
  14. Fuertes, M.A., Alonso, C., Perez, J.M., 2003. Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chemical Reviews. p. 645-662
  15. Gibson, M.K., Li, Y., MurphY, B., Hussain, M.H.A., DeConti, R.C., Ensley, J., Forastiere, A.A., 2005. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395) : An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. American Society of Clinical Oncology. Vol. 23. p. 3562-3567
  16. Hayes, D.M., Cvitkovic, E., Golbey, R.B., Scheiner, E., Helson, L., Krakoff, I.H., 1977. High Dose Cis-Platinum Diammine Dichloride Amelioration of Renal Toxicity by Mannitol Diuresis. Cancer Journal. p. 1372 – 1381
  17. Hesketh, P.J., 2008. Review Article : Chemotherapy-Induced Nausea and Vomiting. The New England Journal of Medicine. Vol. 358 p.2482-2494
  18. Ho, K.M., Sheridan, D.J., 2006. Meta-analysis of furosemide to prevent or treat acute renal failure. British Medical Journal.
  19. Katzung, B.G., Masters, S.B., Trevor, A.J., 2009. Basic and Clinical Pharmacology Eleventh Edition. San Fransisco: McGrawHill Lange
  20. K/DOQI. 2002. Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification, and Stratification. New York: National Kidney Foundation p. 12
  21. KDIGO. 2012. Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. Vol. 2 p. 12
  22. Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., Kaneda, H., Nishina, S., Tsurutani, J., Fujiwara, K., Nomura, M., Yamazoe, Y., Chiba, Y., Nishida, S., Tamura, T., Nakagawa, K., 2014. Risk Factors for Cisplatin-Induced Nephro-toxicity and Potential of Magnesium Supplementation for Renal Protection. Plos One. 9(7)
  23. Kuhlmann, M.K., Burkhardt, G., Kohler, H., 1997. Insights into Potential Cellular Mechanisms of Cisplatin Nephrotoxicity and Their Clinical Appli-cation. Nephrol Dial Transplan ; 12: p. 2478-2480.
  24. Leu, L, Baribeault, D., 2010. A Comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventive measure. Journal of Oncology Pharmacy Practice. Vol. 16 p.167-161
  25. Marceau, D., Poirier, M., Masson, E., Beaulieu, E., 1999. High Incidence of Nephrotoxicity with Cisplatin Therapy Despite Adequate Hydration: Risk Factor Correlations (Meeting abstract). ASCO annual meeting.
  26. Miller, R.P., Tadagavadi, R.K., Ramesh, G., Reeves, W.B., 2010. Review Mechanisms of Cisplatin Nephrotoxicity. Toxins Vol. 2 p. 2490-2518
  27. Moon, H.H., Seo, K.W., Yoon, K.Y., Shin, Y.M., Choi, K.H., Lee, S.H., 2011. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World Journal of Gastroenterology Vol. 17 p. 3510-3517
  28. Morgan, K.P., Snavely, A.C., Wind, L.S., Buie, L.W., Olson, J.G., Walko, C.M., Weiss, J., 2014. Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With dan ithout Mannitol. Sage Journal. Vol 48 (7) p. 863-869
  29. Pabla, N. & Dong, Z., 2008. Review – Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies. Kidney International. p. 994-1007
  30. Pabla, N., Murphy, R.F., Liu, K., Dong, Z., 2009. The copper transporter contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. American Journal of Physiology-Renal Physiology. Vol. 296 p 505-511
  31. Pfister, D.G. et al., 2011. Head and Neck Cancers Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. Volume 9 number 6, p. 596-650
  32. Pfister, D.G. et al., 2013. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck Cancers Version 2.2013. Journal of the National Comprehensive Cancer Network. All right reserved
  33. Ries, F., Klastersky, J., 1986. Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity. American Journal Kidney Disease. Vol. VIII, p. 368-379
  34. Santoso, J.T., Lucci, J.A., Coleman, R.L., Schafer, I., Hannigan, E.V., 2003. Saline, Mannitol & Furosemide Hydration in Acute Cisplatin Nephrotoxicity: A Randomized Trial. Cancer Chemother Pharmacol 2003; chapter 52, p. 13-18
  35. Shawkat, H., Westwood, M., Mortimer, A., 2012. Mannitol : a review of its clinical uses. Oxford University Press on behalf of the British Journal of Anaesthesia. All right reserved
  36. Skeel, R.T., 2007. Handbook of Cancer Chemotherapy 7th Edition : Carcinomas of the Head and Neck. Lippincott Williams & Wilkins. Chapter 6, p. 214-235
  37. Sweetman, S.C., 2009. Martindale – The Complete Drug Reference 36th Edition. London: Pharmaceutical Press, p. 698-700
  38. Tiseo , M., Martelli, O., Mancuso, A., Sormani, M.P., Bruzzi, P., Salvia, R.D., Marinis, F.D., Ardizzoni, A., 2007. Short Hydration Regimen and Nephrotoxicity of Intermediate to High Dose Cisplatin Based Chemotherapy for Outpatirnt Treatment in Lung Cancer and Mesothelioma. Tumori Vol. 93 p. 138-144
  39. UF Med, 2007. Covalent DNA–Binding Drugs. Last updated: January 15, 2007
  40. Vacher, V.L., Rey, J.B., Bagnis, C.I., Deray, G., Daou-phars, M., 2008. Prevention of cisplatin nephro-toxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemotherapy and Pharmacology. Vol. 61 p. 903–909
  41. Vokes, E.E., 2010. Harrison's Hematology and Oncology : Head and Neck Cancer. New York: McGrawHill Medical. Chapter 32, p. 433-438
  42. Yao, X., Panichpisal, K., Kurtzman, N., Nugent, K., 2007. Cisplatin Nephrotoxicity: A Review. The American Journal of the Medicine Sciences. Vol. 334 p. 115-124.